Advanced search
Publication Cover
Acta Oto-Laryngologica Volume 140, 2020 - Issue 4
Submit an article Journal homepage
1,492
Views
0
CrossRef citations to date
0
Altmetric
Oncology

Substantial intrinsic variability in chemoradiosensitivity of newly established anaplastic thyroid cancer cell-lines

Sigurdur GretarssonDepartment of Clinical Sciences Lund, Oto-rhino-laryngology, Head and Neck Surgery, Skåne University Hospital, Lund University, Lund, Sweden; View further author information
,
Alexander NygrenDepartment of Clinical Sciences Lund, Oto-rhino-laryngology, Head and Neck Surgery, Skåne University Hospital, Lund University, Lund, Sweden; View further author information
,
Ann H. RosendahlDepartment of Clinical Sciences Lund, Oncology and Pathology, Skåne University Hospital, Lund University, Lund, Sweden; View further author information
,
Nektaria MylonaDepartment of Pathology, Regional Laboratories Region Skåne, Skåne University Hospital, Lund, Sweden; View further author information
,
Elisabeth KjellénDepartment of Clinical Sciences Lund, Oncology and Pathology, Skåne University Hospital, Lund University, Lund, Sweden; View further author information
,
Yuesheng JinDepartment of Laboratory Medicine, Division of Clinical Genetics, Lund University, Lund, Sweden; View further author information
,
Kajsa PaulssonDepartment of Laboratory Medicine, Division of Clinical Genetics, Lund University, Lund, Sweden; ORCID Iconhttp://orcid.org/0000-0001-7950-222XView further author information
ORCID Icon,
Åke BorgDepartment of Clinical Sciences Lund, Oncology and Pathology, Skåne University Hospital, Lund University, Lund, Sweden; ORCID Iconhttp://orcid.org/0000-0002-5793-132XView further author information
ORCID Icon,
Eva BrunDepartment of Clinical Sciences Lund, Oncology and Pathology, Skåne University Hospital, Lund University, Lund, Sweden; View further author information
,
Jan TennvallDepartment of Clinical Sciences Lund, Oncology and Pathology, Skåne University Hospital, Lund University, Lund, Sweden; View further author information
,
Anders BergenfelzDepartment of Clinical Sciences Lund, Surgery, Skåne University Hospital, Lund University, Lund, SwedenORCID Iconhttp://orcid.org/0000-0002-8355-6025View further author information
ORCID Icon,
Lennart GreiffDepartment of Clinical Sciences Lund, Oto-rhino-laryngology, Head and Neck Surgery, Skåne University Hospital, Lund University, Lund, Sweden; View further author information
,
Johan WennerbergDepartment of Clinical Sciences Lund, Oto-rhino-laryngology, Head and Neck Surgery, Skåne University Hospital, Lund University, Lund, Sweden; View further author information
&
Lars EkbladDepartment of Clinical Sciences Lund, Oncology and Pathology, Skåne University Hospital, Lund University, Lund, Sweden; Correspondence[email protected]
View further author information
 show all
Pages 337-343 | Received 17 Sep 2019, Accepted 02 Dec 2019, Published online: 10 Jan 2020

References

  • Tennvall J, Lundell G, Wahlberg P, et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer. 2002;86(12):1848–1853.
  • Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid. 2000;10(7):587–594.
  • Marlow LA, D’Innocenzi J, Zhang Y, et al. Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target. J Clin Endocrinol Metab. 2010;95(12):5338–5347.
  • Schweppe RE, Klopper JP, Korch C, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008;93(11):4331–4341.
  • Woodward EL, Biloglav A, Ravi N, et al. Genomic complexity and targeted genes in anaplastic thyroid cancer cell lines. Endocr Relat Cancer. 2017;24(5):209–220.
  • Davidsson J, Lilljebjorn H, Panagopoulos I, et al. BRAF mutations are very rare in B- and T-cell pediatric acute lymphoblastic leukemias. Leukemia. 2008;22(8):1619–1621.
  • Nonaka D, Tang Y, Chiriboga L, et al. Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Modern Pathol. 2008;21(2):192–200.
  • Miettinen M, Franssila KO. Variable expression of keratins and nearly uniform lack of thyroid transcription factor 1 in thyroid anaplastic carcinoma. Hum Pathol. 2000;31(9):1139–1145.
  • Paulsson JO, Backman S, Wang N, et al. Whole-genome sequencing of synchronous thyroid carcinomas identifies aberrant DNA repair in thyroid cancer dedifferentiation. J Pathol. 2019. doi:10.1002/path.5359
  • Lee JJ, Foukakis T, Hashemi J, et al. Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models. Thyroid. 2007;17(4):289–301.
  • Roque L, Soares J, Castedo S. Cytogenetic and fluorescence in situ hybridization studies in a case of anaplastic thyroid carcinoma. Cancer Genet Cytogenet. 1998;103(1):7–10.
  • Jenkins RB, Hay ID, Herath JF, et al. Frequent occurrence of cytogenetic abnormalities in sporadic nonmedullary thyroid carcinoma. Cancer. 1990;66(6):1213–1220.
  • Jin Y, Mertens F, Mandahl N, et al. Chromosome abnormalities in eighty-three head and neck squamous cell carcinomas: influence of culture conditions on karyotypic pattern. Cancer Res. 1993;53(9):2140–2146.
  • Guerrero AA, Gamero MC, Trachana V, et al. Centromere-localized breaks indicate the generation of DNA damage by the mitotic spindle. Proc Natl Acad Sci U S A. 2010;107(9):4159–4164.
  • Ain KB, Tofiq S, Taylor KD. Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab. 1996;81(10):3650–3653.
  • Guerra A, Di Crescenzo V, Garzi A, et al. Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review. BMC Surg. 2013;13(Suppl 2):S44.
  • Kurata K, Onoda N, Noda S, et al. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells. Int J Oncol. 2016;49(6):2303–2308.
  • Rosove MH, Peddi PF, Glaspy JA. BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med. 2013;368(7):684–685.
  • Marten KA, Gudena VK. Use of vemurafenib in anaplastic thyroid carcinoma: a case report. Cancer Biol Ther. 2015;16(10):1430–1433.
  • Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. JCO. 2018;36(1):7–13.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.